Follow on Google News News By Tag * Diabetes * Blood Glucose * Self Monitoring * Diabetes Care * Diabetes Technology Therapeutics * Smbg * Hba1c * Glucose Meters * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | Special Supllement on Self-Monitoring of Blood Glucose in Diabetes Technology and TherapeuticsSubjects with type 1 or type 2 diabetes who self-monitor their blood glucose levels more frequently and use the results to adjust treatment regimens can achieve improved glucose control.
Self-Monitoring of Blood Glucose Highly Effective in Diabetes Care, According to a Special Issue of Diabetes Technology and Therapeutics New Rochelle, NY—Subjects with type 1 or type 2 diabetes who self-monitor their blood glucose levels more frequently and use the results to adjust treatment regimens can achieve improved glucose control, according to a collection of state-of-the- “Increased frequency of self-monitoring of blood glucose (SMBG) has been shown to significantly improve glucose control. SMBG not only complements A1C results, it guides the patient for self-management of diabetes at home on a day-to-day basis,” writes Editor-in-Chief, Satish K. Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado at Denver and Health Sciences Center, in a supplement overview. Spanning the clinical, practical, and economic implications of SMBG, the supplement includes papers probing the technology behind state-of-the- Shoba Subramanian, MD, and Irl Hirsch, MD, of the University of Washington, Seattle, review the evidence supporting frequent SMBG, recent advances in glucose meters and SMBG data processing and how it can be applied for more effective type 1 diabetes management, as well as the potential barriers to use of frequent SMBG that limit its applicability, in an article entitled, “The Utility and Recent Advances in Self-Monitoring of Blood Glucose in Type 1 Diabetes.” Focusing on type 2 diabetes, Nalinee Poolsup, PhD, from Silpakorn University, Nakhon-Pathom, Thailand, and Naeti Suksomboon, PharmD, PhD and Warisara Jiamsathit, MScPharm, from Mahidol University, Bangkok, Thailand, conclude that SMBG can yield a significant decrease in HbA1C levels in patients with type 2 diabetes when the results of SMBG are used to adjust therapeutic regimens. They describe the benefits of SMBG in “Systematic Review of the Benefits of Self-Monitoring of Blood Glucose on Glycemic Control in Type 2 Diabetes Patients.” In a forward-looking report entitled, “The Future of Self-Monitored Blood Glucose: Mean Blood Glucose Versus Glycosylated Hemoglobin,” Diabetes Technology & Therapeutics is a peer-reviewed journal published bimonthly that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Technologies include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed online at http://www.liebertpub.com/ Mary Ann Liebert, Inc., is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including, Thyroid, Metabolic Syndrome and Related Disorders, Obesity Management, and Journal of Aerosol Medicine and Pulmonary Drug Delivery. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 60 journals, books, and newsmagazines is available at www.liebertpub.com Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 www.liebertpub.com Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101 # # # Mary Ann Liebert, Inc., is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 60 journals, books, and newsmagazines is available at www.liebertpub.com Website: www.liebertpub.com End
Account Email Address Disclaimer Report Abuse
|
|